IPH — Innate Pharma SA Share News
0.000.00%
Last trade - 00:00- €121.51m
- €130.82m
- €2.79m
France's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member
French and Benelux stocks-Factors to watch
Brief: Innate Pharma FY Operating Expenses EUR -71.696 Million
Innate Pharma jumps on FDA's 'breakthrough therapy' tag for skin cancer therapy
Brief: Innate Pharma Shares Updated Results From The Sanofi Developed Blood Cancer Phase 1/2 Sar443579/Iph6101 Trial
Brief: Innate Pharma: Positive Results From Tellomak Phase 2 Study With Lacutamab
Brief: Innate Pharma End-March Cash Position Of EUR 113.9 Mln
Brief: Innate Pharma Announces Advancement Of Sanofi-Sponsored Clinical Trial For Blood Cancer Patients
Brief: Innate Pharma Says Preclinical Efficacy And Toxicology Data Support Further Development Of IPH45
Brief: Innate Pharma 2023 Net Loss EUR 7.6 Mln, Vs EUR 58.1 Mln YoY
Brief: Innate Pharma FY Basic EPS EUR -0.09
Brief: Innate Pharma: First Patient Dosed In Study Of IPH6501 In Non-Hodgkin's Lymphoma
Brief: Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold On Lacutamab Clinical Program
Innate Pharma jumps on new licensing to Sanofi
Brief: Innate Pharma Announces Licensing Of Fourth Natural Killer Cell Engager In Oncology To Sanofi
Brief: CEO Mondher Mahjoubi To Leave Innate Pharma